BioMarin EVP Friberg sells 6,326 company shares

BIOMARIN PHARMACEUTICAL INC executive Gregory R. Friberg, EVP and Chief R&D Officer, reported an open-market sale of 6,326 shares of common stock on February 26, 2026.

Rhea-AI Filing Summary

BIOMARIN PHARMACEUTICAL INC executive Gregory R. Friberg, EVP and Chief R&D Officer, reported an open-market sale of 6,326 shares of common stock on February 26, 2026. The shares were sold at a weighted average price of $60.3758 per share, with individual sale prices ranging from $60.36 to $60.51 according to the footnote. After this transaction, Friberg directly holds 37,578 shares of BioMarin common stock.

Insider Trade Summary

Net Seller: 6,326 shares

Net Sell 1 txn

Insider Friberg Gregory R

Role EVP, Chief R&D Officer

Sold 6,326 shs ($382K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,326	$60.3758	$382K

Holdings After Transaction: Common Stock — 37,578 shares (Direct)

Footnotes (1)

1. F1. The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.36 to $60.51. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioMarin (BMRN) report for Gregory R. Friberg?

Gregory R. Friberg reported selling 6,326 shares of BioMarin common stock. The transaction was an open-market sale by the EVP and Chief R&D Officer, reflecting a routine insider trade rather than a change in company operations or strategy.

At what price did Gregory R. Friberg sell BioMarin (BMRN) shares?

The shares were sold at a weighted average price of $60.3758 per share. A footnote explains the actual sale prices ranged from $60.36 to $60.51, indicating multiple trades were executed within that narrow price range.

How many BioMarin (BMRN) shares does Gregory R. Friberg own after the sale?

After the reported sale, Gregory R. Friberg directly owns 37,578 shares of BioMarin common stock. This remaining stake reflects his ongoing equity interest in the company following the 6,326-share open-market disposition.

What does the Form 4 footnote say about Gregory R. Friberg’s BioMarin (BMRN) trade prices?

The footnote states the column 4 price is a weighted average and that sale prices ranged from $60.36 to $60.51. It also notes Friberg will provide detailed price-breakdown information to the issuer, security holders, or SEC staff upon request.

Was Gregory R. Friberg’s BioMarin (BMRN) transaction a buy or a sell?

The transaction was a sell. Gregory R. Friberg executed an open-market sale of 6,326 shares of BioMarin common stock, as indicated by the transaction code “S” and the classification as an open-market sale on the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 08:39 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Friberg Gregory R

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief R&D Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		S		6,326	D	$60.3758(1)	37,578	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.36 to $60.51. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.